Corrigendum to "A Phase III, multicenter, randomized, double-blind, active comparator-controlled study to evaluate the safety, tolerability, and immunogenicity of V114 compared with PCV13 in healthy infants (PNEU-PED-EU-1)" [Vaccine 41 (2023) 3387-3398].
Martinon-Torres F, Wysocki J, Szenborn L, Carmona-Martinez A, Poder A, Dagan R, Richmond P, Gilbert C, Trudel MC, Flores S, Lupinacci R, McFetridge R, Wiedmann RT, Chen Q, Gerrits H, Banniettis N, Musey L, Bickham K, Kaminski J; V114-025 PNEU-PED-EU-1 study group.
Martinon-Torres F, et al. Among authors: banniettis n.
Vaccine. 2025 Feb 27;48:126628. doi: 10.1016/j.vaccine.2024.126628. Epub 2025 Jan 20.
Vaccine. 2025.
PMID: 39837003
Free article.
No abstract available.